Actively Recruiting
Study to Evaluate Safety and Effectiveness of Oral STL303 Compared to Placebo in Adults With Geographic Atrophy Caused by Age-related Macular Degeneration
Led by Sitala Bio LTD · Updated on 2026-09-21
300
Participants Needed
56
Research Sites
56 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of STL303 in adults with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD. GA leads to gradual cell death in the back of the eye, causing blurry or missing central vision spots. This randomized, double-masked, multi-center study aims to find the best dose of STL303 and assess its impact on this eye condition. Participants will be randomly assigned to receive either one of two doses of oral STL303 or a placebo. The study compares these groups to understand how STL303 affects the rate of vision loss and other eye health measures. The treatment period lasts up to 104 weeks, with evaluations continuing through week 108 to monitor safety and disease progression. During the study, participants will undergo regular eye exams, including imaging scans and vision tests, to track changes in their condition. Researchers will measure the reduction in the area of eye damage, retinal sensitivity, and vision-related quality of life. Blood samples will be collected at scheduled visits to analyze how the drug is processed in the body. Participants will also record daily medication use and attend frequent study visits for assessments and safety monitoring. The total trial participation may last several years until study completion in 2029.
CONDITIONS
Brief Title
A Study in Adults With Geographic Atrophy
Research Team
C
Clinical Operations Manager
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here